ELI LILLY AND COMPANY

NYSE: LLY (Eli Lilly and Company)

Kemas kini terakhir: 2 hari lalu, 5:05AM

738.21

-50.88 (-6.45%)

  • 1H -6.45%
  • 5H -10.25%
  • 1B -15.11%
  • 6B -17.83%
  • Tahun Ke Tarikh -5.12%
  • 1T -5.03%
  • 5T 420.31%
Penutupan Terdahulu 789.09
Buka 762.11
Jumlah Dagangan 4,546,127
Purata Dagangan (3B) 3,702,946
Modal Pasaran 662,904,504,320
Harga / Pendapatan (P/E TTM) 62.88
Harga / Pendapatan (P/E Ke hadapan) 35.97
Harga / Jualan (P/S) 16.51
Harga / Buku (P/B) 52.04
Julat 52 Minggu
711.40 (-3%) — 972.53 (31%)
Tarikh Pendapatan 1 May 2025
Hasil Dividen (DY TTM) 0.73%
Margin Keuntungan 23.51%
Margin Operasi (TTM) 42.84%
EPS Cair (TTM) 11.68
Pertumbuhan Hasil Suku Tahunan (YOY) 44.70%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 101.40%
Jumlah Hutang/Ekuiti (D/E MRQ) 244.62%
Nisbah Semasa (MRQ) 1.15
Aliran Tunai Operasi (OCF TTM) 8.82 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 1.32 B
Pulangan Atas Aset (ROA TTM) 15.33%
Pulangan Atas Ekuiti (ROE TTM) 84.26%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Menaik
Drug Manufacturers - General (Global) Menaik Menaik
Stok Eli Lilly and Company Menaik Menaik

AISkor Stockmoo

1.9
Konsensus Penganalisis 5.0
Aktiviti Orang Dalam NA
Volatiliti Harga 4.5
Purata Bergerak Teknikal -1.5
Osilator Teknikal -0.5
Purata 1.88

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
LLY 663 B 0.73% 62.88 52.04
NVO 295 B 2.40% 20.46 16.26
NVS 212 B 3.44% 18.03 4.75
MRK 206 B 3.88% 12.09 4.44
JNJ 363 B 3.29% 26.01 5.39
ABBV 331 B 3.36% 78.23 99.47

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Growth
% Dimiliki oleh Orang Dalam 0.17%
% Dimiliki oleh Institusi 83.58%

Pemilikan

Nama Tarikh Syer Dipegang
Lilly Endowment Inc 31 Dec 2024 96,891,978
1,193.301,193.30913.40913.40633.50633.50353.60353.6073.7073.70Harga Sasaran MedianQ2 '20Q2 '20Q3 '20Q3 '20Q4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25
Julat 52 Minggu
711.40 (-3%) — 972.53 (31%)
Julat Harga Sasaran
1,038.00 (-99%) — 1,190.00 (-99%)
Tinggi 1,190.00 (Citigroup, 61.20%) Beli
Median 1,100.00 (49.01%)
Rendah 1,038.00 (Truist Securities, 40.61%) Beli
Purata 1,109.33 (50.27%)
Jumlah 3 Beli
Harga Purata @ Panggilan 848.38
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Wells Fargo 05 Mar 2025 1,100.00 (49.01%) Beli 929.72
28 Jan 2025 970.00 (31.40%) Beli 804.99
Truist Securities 03 Feb 2025 1,038.00 (40.61%) Beli 810.43
Citigroup 28 Jan 2025 1,190.00 (61.20%) Beli 804.99

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
01 Apr 2025 CNBC Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaro
30 Mar 2025 Pengumuman Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels
29 Mar 2025 CNBC Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
27 Mar 2025 Pengumuman LillyDirect platform expands to facilitate access to Alzheimer's disease care
26 Mar 2025 Pengumuman Direxion Expands Single Stock Leveraged & Inverse ETF Lineup for Exposure to Eli Lilly & Palo Alto Networks
25 Mar 2025 Pengumuman Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
25 Mar 2025 Pengumuman Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
24 Mar 2025 CNBC Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
22 Mar 2025 CNBC Zepbound copycats remain online despite FDA ban
18 Mar 2025 Pengumuman Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound
08 Mar 2025 Pengumuman Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
07 Mar 2025 Pengumuman Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis
05 Mar 2025 CNBC Amgen starts two critical late-stage trials for weight loss drug MariTide
05 Mar 2025 CNBC Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy
28 Feb 2025 Pengumuman Lilly to participate in Leerink Partners Global Healthcare Conference
28 Feb 2025 Pengumuman Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor
26 Feb 2025 Pengumuman Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion
26 Feb 2025 CNBC Eli Lilly plans at least $27 billion in new U.S. manufacturing investments
25 Feb 2025 Pengumuman Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company
25 Feb 2025 Pengumuman Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients
25 Feb 2025 CNBC Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access
21 Feb 2025 CNBC Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
20 Feb 2025 CNBC Eli Lilly aims to invest in 'big problems hiding in plain sight' using obesity windfall 
20 Feb 2025 CNBC From pills to new uses, here's what Eli Lilly’s top scientist sees as the future of weight loss drugs
18 Feb 2025 Pengumuman Lilly to participate in TD Cowen's 45th Annual Health Care Conference
07 Feb 2025 Pengumuman Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
06 Feb 2025 CNBC Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
06 Feb 2025 Pengumuman Lilly reports full Q4 2024 financial results and provides 2025 guidance
06 Feb 2025 CNBC Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
05 Feb 2025 CNBC Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
28 Jan 2025 CNBC Food-as-medicine startups hope Kennedy, if confirmed as HHS secretary, will boost their businesses
28 Jan 2025 CNBC FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
27 Jan 2025 CNBC Pharma is hopeful about Trump's second term — here's what to expect for drugmakers
23 Jan 2025 Pengumuman Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement
17 Jan 2025 CNBC Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
15 Jan 2025 Pengumuman FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
15 Jan 2025 CNBC Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
14 Jan 2025 Pengumuman Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance
14 Jan 2025 CNBC Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
13 Jan 2025 Pengumuman Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program
13 Jan 2025 CNBC Eli Lilly CEO expects new weight loss pill to be approved next year
13 Jan 2025 CNBC High cost of weight loss drugs drives employers to require nutrition counseling, in boost for startups
09 Jan 2025 CNBC Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says
07 Jan 2025 Pengumuman Lilly to participate in J.P. Morgan Healthcare Conference
Papar semua
Hasil Dividen (DY TTM) 0.73%
Purata Hasil Dividen 5T 1.10%
Nisbah Pembayaran 44.41%
Jangkaan Pembayaran Dividen Seterusnya Sep 2025
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
14 Feb 2025 09 Dec 2024 10 Mar 2025 1.5 Tunai
15 Nov 2024 28 Oct 2024 10 Dec 2024 1.3 Tunai
15 Aug 2024 24 Jun 2024 10 Sep 2024 1.3 Tunai
15 May 2024 06 May 2024 10 Jun 2024 1.3 Tunai
14 Feb 2024 08 Dec 2023 08 Mar 2024 1.3 Tunai
14 Nov 2023 01 Nov 2023 08 Dec 2023 1.13 Tunai
14 Aug 2023 26 Jun 2023 08 Sep 2023 1.13 Tunai
12 May 2023 01 May 2023 09 Jun 2023 1.13 Tunai
14 Feb 2023 12 Dec 2022 10 Mar 2023 1.13 Tunai
14 Nov 2022 17 Oct 2022 09 Dec 2022 0.98 Tunai
12 Aug 2022 27 Jun 2022 09 Sep 2022 0.98 Tunai
13 May 2022 02 May 2022 10 Jun 2022 0.98 Tunai
14 Feb 2022 13 Dec 2021 10 Mar 2022 0.98 Tunai
12 Nov 2021 18 Oct 2021 10 Dec 2021 0.85 Tunai
12 Aug 2021 29 Jun 2021 10 Sep 2021 0.85 Tunai
13 May 2021 03 May 2021 10 Jun 2021 0.85 Tunai
11 Feb 2021 14 Dec 2020 10 Mar 2021 0.85 Tunai
12 Nov 2020 19 Oct 2020 10 Dec 2020 0.74 Tunai
13 Aug 2020 15 Jul 2020 10 Sep 2020 0.74 Tunai
14 May 2020 04 May 2020 10 Jun 2020 0.74 Tunai
13 Feb 2020 16 Dec 2019 10 Mar 2020 0.74 Tunai
14 Nov 2019 22 Oct 2019 10 Dec 2019 0.645 Tunai
14 Aug 2019 20 Jun 2019 10 Sep 2019 0.645 Tunai
16 May 2019 07 May 2019 10 Jun 2019 0.645 Tunai
14 Feb 2019 19 Dec 2018 08 Mar 2019 0.645 Tunai
14 Nov 2018 16 Oct 2018 10 Dec 2018 0.5625 Tunai
14 Aug 2018 19 Jun 2018 10 Sep 2018 0.5625 Tunai
16 May 2018 07 May 2018 08 Jun 2018 0.5625 Tunai
14 Feb 2018 11 Dec 2017 09 Mar 2018 0.5625 Tunai
14 Nov 2017 16 Oct 2017 08 Dec 2017 0.52 Tunai
11 Aug 2017 19 Jun 2017 08 Sep 2017 0.52 Tunai
11 May 2017 01 May 2017 09 Jun 2017 0.52 Tunai
13 Feb 2017 12 Dec 2016 10 Mar 2017 0.52 Tunai
10 Nov 2016 17 Oct 2016 09 Dec 2016 0.51 Tunai
11 Aug 2016 20 Jun 2016 09 Sep 2016 0.51 Tunai
11 May 2016 02 May 2016 10 Jun 2016 0.51 Tunai
10 Feb 2016 08 Dec 2015 10 Mar 2016 0.51 Tunai
10 Nov 2015 19 Oct 2015 10 Dec 2015 0.5 Tunai
12 Aug 2015 15 Jun 2015 10 Sep 2015 0.5 Tunai
14 May 2015 04 May 2015 10 Jun 2015 0.5 Tunai
11 Feb 2015 15 Dec 2014 10 Mar 2015 0.5 Tunai
12 Nov 2014 20 Oct 2014 10 Dec 2014 0.49 Tunai
13 Aug 2014 16 Jun 2014 10 Sep 2014 0.49 Tunai
13 May 2014 05 May 2014 10 Jun 2014 0.49 Tunai
12 Feb 2014 16 Dec 2013 10 Mar 2014 0.49 Tunai
13 Nov 2013 21 Oct 2013 10 Dec 2013 0.49 Tunai
13 Aug 2013 18 Jun 2013 10 Sep 2013 0.49 Tunai
14 May 2013 03 May 2013 10 Jun 2013 0.49 Tunai
13 Feb 2013 17 Dec 2012 08 Mar 2013 0.49 Tunai
13 Nov 2012 15 Oct 2012 10 Dec 2012 0.49 Tunai
13 Aug 2012 19 Jun 2012 10 Sep 2012 0.49 Tunai
13 Feb 2012 12 Dec 2011 09 Mar 2012 0.49 Tunai
10 Nov 2011 17 Oct 2011 09 Dec 2011 0.49 Tunai
11 Aug 2011 20 Jun 2011 09 Sep 2011 0.49 Tunai
11 May 2011 18 Apr 2011 10 Jun 2011 0.49 Tunai
11 Feb 2011 13 Dec 2010 10 Mar 2011 0.49 Tunai
10 Nov 2010 18 Oct 2010 10 Dec 2010 0.49 Tunai
11 Aug 2010 21 Jun 2010 10 Sep 2010 0.49 Tunai
12 May 2010 19 Apr 2010 10 Jun 2010 0.49 Tunai
10 Feb 2010 14 Dec 2009 10 Mar 2010 0.49 Tunai
10 Nov 2009 19 Oct 2009 10 Dec 2009 0.49 Tunai
12 Aug 2009 22 Jun 2009 10 Sep 2009 0.49 Tunai
13 May 2009 20 Apr 2009 10 Jun 2009 0.49 Tunai
11 Feb 2009 15 Dec 2008 10 Mar 2009 0.49 Tunai
12 Nov 2008 20 Oct 2008 10 Dec 2008 0.47 Tunai
13 Aug 2008 20 Jun 2008 10 Sep 2008 0.47 Tunai
13 Feb 2008 17 Dec 2007 10 Mar 2008 0.47 Tunai
13 Nov 2007 15 Oct 2007 10 Dec 2007 0.425 Tunai
13 Aug 2007 21 Jun 2007 10 Sep 2007 0.425 Tunai
11 May 2007 16 Apr 2007 08 Jun 2007 0.425 Tunai
13 Feb 2007 18 Dec 2006 09 Mar 2007 0.425 Tunai
13 Nov 2006 16 Oct 2006 08 Dec 2006 0.4 Tunai
11 Aug 2006 26 Jun 2006 08 Sep 2006 0.4 Tunai
11 May 2006 24 Apr 2006 09 Jun 2006 0.4 Tunai
13 Feb 2006 19 Dec 2005 10 Mar 2006 0.4 Tunai
10 Nov 2005 17 Oct 2005 09 Dec 2005 0.38 Tunai
11 Aug 2005 24 Jun 2005 09 Sep 2005 0.38 Tunai
11 May 2005 18 Apr 2005 10 Jun 2005 0.38 Tunai
11 Feb 2005 20 Dec 2004 10 Mar 2005 0.38 Tunai
10 Nov 2004 18 Oct 2004 10 Dec 2004 0.355 Tunai
11 Aug 2004 28 Jun 2004 10 Sep 2004 0.355 Tunai
12 May 2004 19 Apr 2004 10 Jun 2004 0.355 Tunai
11 Feb 2004 15 Dec 2003 10 Mar 2004 0.355 Tunai
12 Nov 2003 20 Oct 2003 10 Dec 2003 0.335 Tunai
13 Aug 2003 23 Jun 2003 10 Sep 2003 0.335 Tunai
13 May 2003 28 Apr 2003 10 Jun 2003 0.335 Tunai
12 Feb 2003 16 Dec 2002 10 Mar 2003 0.335 Tunai
13 Nov 2002 21 Oct 2002 10 Dec 2002 0.31 Tunai
13 Aug 2002 24 Jun 2002 10 Sep 2002 0.31 Tunai
13 May 2002 15 Apr 2002 10 Jun 2002 0.31 Tunai
13 Feb 2002 17 Dec 2001 08 Mar 2002 0.31 Tunai
13 Nov 2001 15 Oct 2001 10 Dec 2001 0.28 Tunai
13 Aug 2001 25 Jun 2001 10 Sep 2001 0.28 Tunai
11 May 2001 16 Apr 2001 11 Jun 2001 0.28 Tunai
13 Feb 2001 18 Dec 2000 09 Mar 2001 0.28 Tunai
13 Nov 2000 16 Oct 2000 11 Dec 2000 0.26 Tunai
11 Aug 2000 26 Jun 2000 11 Sep 2000 0.26 Tunai
11 May 2000 17 Apr 2000 09 Jun 2000 0.26 Tunai
11 Feb 2000 20 Dec 1999 10 Mar 2000 0.26 Tunai
10 Nov 1999 18 Oct 1999 10 Dec 1999 0.23 Tunai
11 Aug 1999 19 Jul 1999 10 Sep 1999 0.23 Tunai
12 May 1999 19 Apr 1999 10 Jun 1999 0.23 Tunai
10 Feb 1999 21 Dec 1998 10 Mar 1999 0.23 Tunai
10 Nov 1998 20 Oct 1998 10 Dec 1998 0.2 Tunai
12 Aug 1998 20 Jul 1998 10 Sep 1998 0.2 Tunai
13 May 1998 20 Apr 1998 10 Jun 1998 0.2 Tunai
11 Feb 1998 15 Dec 1997 10 Mar 1998 0.2 Tunai
12 Nov 1997 15 Sep 1997 10 Dec 1997 0.2 Tunai
13 Aug 1997 21 Jul 1997 10 Sep 1997 0.36 Tunai
13 May 1997 21 Apr 1997 10 Jun 1997 0.36 Tunai
12 Feb 1997 16 Dec 1996 10 Mar 1997 0.36 Tunai
13 Nov 1996 21 Oct 1996 10 Dec 1996 0.3425 Tunai
13 Aug 1996 15 Jul 1996 10 Sep 1996 0.3425 Tunai
13 May 1996 15 Apr 1996 10 Jun 1996 0.3425 Tunai
13 Feb 1996 18 Dec 1995 11 Mar 1996 0.3425 Tunai
13 Nov 1995 17 Oct 1995 11 Dec 1995 0.685 Tunai
11 Aug 1995 17 Jul 1995 11 Sep 1995 0.645 Tunai
09 May 1995 17 Apr 1995 12 Jun 1995 0.645 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 1.50 1 0.20
2024 5.20 4 0.67
2023 4.52 4 0.78
2022 3.92 4 1.07
2021 3.40 4 1.23
2020 2.96 4 1.75
2019 2.58 4 1.96
2018 2.25 4 1.94
2017 2.08 4 2.46
2016 2.04 4 2.77
2015 2.00 4 2.37
2014 1.96 4 2.84
2013 1.96 4 3.84
2012 1.47 3 2.98
2011 1.96 4 4.72
2010 1.96 4 5.59
2009 1.96 4 5.49
2008 1.41 3 3.50
2007 1.70 4 3.18
2006 1.60 4 3.07
2005 1.52 4 2.69
2004 1.42 4 2.50
2003 1.34 4 1.91
2002 1.24 4 1.95
2001 1.12 4 1.43
2000 1.04 4 1.12
1999 0.920 4 1.38
1998 0.800 4 0.90
1997 1.28 4 1.84
1996 1.37 4 3.75
1995 1.98 3 7.02
Papar semua
876.07876.07824.66824.66773.26773.26721.85721.85670.44670.44Mar 26Mar 26Mar 27Mar 27Mar 28Mar 28Mar 31Mar 31Apr 1Apr 1Apr 2Apr 2Apr 3Apr 3Apr 4Apr 4

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.0000.000-5.000-5.000-10.000-10.000-15.000-15.000-20.000-20.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda